RemeGen Co., Ltd. (HKG:9995)
Hong Kong
· Delayed Price · Currency is HKD 41.35
+6.05 (17.14%)
Apr 24, 2025, 4:08 PM HKT
RemeGen Revenue
In the year 2024, RemeGen had annual revenue of 1.72B CNY with 58.54% growth. RemeGen had revenue of 507.99M in the quarter ending December 31, 2024, with 62.05% growth.
Revenue
1.72B CNY
Revenue Growth
+58.54%
P/S Ratio
14.72
Revenue / Employee
572.48K CNY
Employees
2,999
Market Cap
26.90B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| CSPC Pharmaceutical Group | 30.87B |